Allarity Therapeutics
ALLR
10 hedge funds and large institutions have $197K invested in Allarity Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
128% more capital invested
Capital invested by funds: $86.5K → $197K (+$111K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
11% more funds holding
Funds holding: 9 → 10 (+1)
0.79% less ownership
Funds ownership: 2.08% → 1.29% (-0.79%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$48.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$45.1K |
| 3 |
Jane Street
New York
|
+$24.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.8K |
| 5 |
Squarepoint
New York
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$21.8K |
| 2 |
CCM
Corsair Capital Management
New York
|
-$18.7K |
| 3 |
Barclays
London,
United Kingdom
|
-$9.44K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
1
XTX Topco
George Town,
Cayman Islands
| $51.5K | +$48.2K | +50,950 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $51.2K | +$15.8K | +16,729 | +49% |
|
|
3
UBS Group
Zurich,
Switzerland
| $48.5K | +$45.1K | +47,684 | +15,895% |
|
|
4
Jane Street
New York
| $26.6K | +$24.9K | +26,365 | New |
|
|
5
Squarepoint
New York
| $14.6K | +$13.7K | +14,450 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $3.1K | -$1.54K | -1,632 | -35% |
|
7
Citigroup
New York
| $1.49K | +$1.39K | +1,472 | New |
|
8
Bank of America
Charlotte,
North Carolina
| $139 | +$95 | +100 | +263% |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $7 | – | – | – |
|
|
DB
10
Danske Bank
Copenhagen K,
Denmark
| $1 | – | – | – |
|
|
11
Morgan Stanley
New York
| – | -$21.8K | -23,311 | Closed |
|
|
CCM
12
Corsair Capital Management
New York
| – | -$18.7K | -20,000 | Closed |
|
|
13
Barclays
London,
United Kingdom
| – | -$9.44K | -10,078 | Closed |
|
ALLR Hedge Fund Activity: Q2 2025 in Review
10 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q2 2025, worth a combined $197K — up 128% from $86.5K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ALLR positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $48.2K. The largest seller was Morgan Stanley, exiting entirely with an estimated $21.8K sold.
- 10 institutional investors held Allarity Therapeutics (ALLR) as of Q2 2025, up from 9 in Q1 2025.
- Funds reported $197K of Allarity Therapeutics stock for Q2 2025, up 128% quarter-over-quarter.
- 4 funds opened new Allarity Therapeutics positions in Q2 2025 and 3 closed out, a net change of +1 holder.
- The largest Allarity Therapeutics buyer in Q2 2025 was XTX Topco, an estimated $48.2K added.
- The largest Allarity Therapeutics seller in Q2 2025 was Morgan Stanley, an estimated $21.8K sold.
Based on aggregated 13F filings for Q2 2025.